Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment

Growing evidence advanced the idea that the soluble form of the receptor for advanced glycation end-products (sRAGE) might serve as a risk marker for several disorders including Alzheimer disease. We found a reduced level of circulating sRAGE in patients with mild cognitive impairment (MCI). The red...

Full description

Saved in:
Bibliographic Details
Published inJournal of Neural Transmission Vol. 115; no. 7; pp. 1047 - 1050
Main Authors Ghidoni, R., Benussi, L., Glionna, M., Franzoni, M., Geroldi, D., Emanuele, E., Binetti, G.
Format Journal Article
LanguageEnglish
Published Vienna Springer Vienna 01.07.2008
Springer Nature B.V
Subjects
Age of Onset
Aged
Alzheimer's Disease and Related Disorders - Short Communication
Case-Control Studies
Cognition Disorders - blood
Female
Humans
Male
Medicine
Medicine & Public Health
Neurology
Neurosciences
Psychiatry
Receptor for Advanced Glycation End Products
Receptors, Immunologic - blood
Statistics as Topic
Cognitive decline
Biological marker
Plasma
sRAGE
AD
Mild cognitive impairment
Online AccessGet full text
ISSN0300-9564
1435-1463
DOI10.1007/s00702-008-0069-9

Cover

More Information
Summary:Growing evidence advanced the idea that the soluble form of the receptor for advanced glycation end-products (sRAGE) might serve as a risk marker for several disorders including Alzheimer disease. We found a reduced level of circulating sRAGE in patients with mild cognitive impairment (MCI). The reduction of sRAGE in MCI, as well as the anticipation of the disease in patients with the lowest sRAGE levels (≤225 pg/ml), suggest a role of the RAGE axis in the pathogenesis of the disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ISSN:0300-9564
1435-1463
DOI:10.1007/s00702-008-0069-9